ALPS Medical Breakthroughs ETF (NY:SBIO)

52.22 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ALPS Medical Breakthroughs ETF

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

March 09, 2026

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

Via Stocktwits

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗

March 02, 2026

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Via Stocktwits

Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗

February 27, 2026

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

Via Stocktwits

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗

January 09, 2026

Via Stocktwits

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder ↗

February 25, 2026

The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

Via Stocktwits

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

January 08, 2026

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Via Stocktwits

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗

December 04, 2025

DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Via Stocktwits

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens ↗

May 23, 2025

Via Stocktwits

Topics Artificial Intelligence

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed ↗

April 15, 2025

The company expects to announce a new CFO “in the coming months.”

Via Stocktwits

Topics Earnings

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗

January 17, 2025

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Via Stocktwits

5 Small-Cap ETFs At The Forefront Of The Latest Rally ↗

July 18, 2024

We have highlighted ETFs from the space that are at the forefront of the market rally over the past week.

Via Talk Markets

Topics ETFs

The Short-Term Trend Is Uncertain, But Stocks Are Showing Momentum ↗

February 18, 2024

I'm still not certain about the short-term trend in the markets, but I can see that most stocks are now showing bullish, upward momentum. Although the PMO index has been choppy over the last four...

Via Talk Markets

5 Market-Beating Sector ETFs Of December ↗

December 30, 2023

Wall Street sizzled in December. The rally came on the back of optimism that the Fed would cut its interest rates sooner than expected and that the U.S. economy would avoid a recession. Here is a look...

Via Talk Markets

Topics ETFs Economy

5 Top-Performing Sector ETFs Of Q2 ↗

June 30, 2023

There are winners from many corners of the space. Here is one ETF each from the five best sectors of the second quarter.

Via Talk Markets

Biotech ETFs Pop On M&A Resurgence ↗

May 10, 2023

The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A).

Via Talk Markets

5 Sector ETFs That Beat the Market in Apri ↗

May 02, 2023

While most of the segments rallied last month, these five ETFs from different corners of the market led the way higher.

Via Talk Markets

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

5 ETFs Riding High On The Biotech Comeback ↗

July 09, 2022

The high-growth biotech segment has borne the maximum brunt of the broader market sell-off.

Via Talk Markets

7 Best Biotech Stocks to Buy in July 2022 ↗

July 08, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Via InvestorPlace

Biotech ETFs That Outperformed Last Week ↗

December 20, 2021

Though the broad U.S. market saw a tumultuous ride last week with most of the sectors in red, biotechnology was the biggest gainer.

Via Talk Markets

Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index ↗

December 17, 2021

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:

Via Benzinga

Top-Performing Biotech ETFs of Last Week ↗

June 14, 2021

Investors may want to tap the bullishness in the biotech sector with the best biotech ETFs of last week.

Via Talk Markets

5 Small-Cap Sector ETFs Leading the Russell 2000 Rally ↗

June 09, 2021

Here are five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month and are likely to continue their strong performance for the rest of the year.

Via Talk Markets

Medical Miracles Inside Biotech ETFs ↗

May 24, 2021

The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and...

Via Talk Markets

Topics Intellectual Property

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.